Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR3 | O15455 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878110 | 1.00 | TLR3 (0.41) | TLR3NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL2875838 | 0.82 | KCNA5 (0.42) | TLR3NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL2875841 | 0.82 | KCNA5 (0.42) | TLR3NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL7258461 | 0.73 | TAAR1 (0.44) | ALDH1A1MAPTTAAR1HTTGRIN2B | |
| SCHEMBL2882211 | 0.69 | NPC1 (0.48) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL2876618 | 0.69 | NPC1 (0.48) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL2882213 | 0.69 | NPC1 (0.48) | NPC1RAB9AALDH1A1MAPTMEN1 | |
| SCHEMBL2891151 | 0.68 | TLR3 (0.39) | TLR3NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL2877927 | 0.68 | TLR3 (0.39) | TLR3NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL11287989 | 0.68 | ALDH1A1 (0.44) | ALDH1A1MAPTTAAR1CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102190661-B | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD | 2013-07-31 | — | — | CN | disclosed |
| CN-102190661-A | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD | 2011-09-21 | — | — | CN | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| EP-1732929-B1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| CN-101429200-A | Tricyclic benzopyran compound as anti-arrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-1934116-A | Tricyclic benzopyran compounds useful as antiarrhythmic agents | NISSAN CHEMICAL IND LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | TLR3 2250/4885NPC1 3313/4885RAB9A 774/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | TLR3 3106/4885NPC1 3638/4885RAB9A 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.